Predicting human immunodeficiency virus type 1-positive sera by using two enzyme immunoassay kits in a parallel testing format. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Predicting human immunodeficiency virus type 1-positive sera by using two enzyme immunoassay kits in a parallel testing format.

J Clin Microbiol. 1991 Nov;29(11):2507-12. Unique Identifier : AIDSLINE MED/92129520
Fonseca K; Anand CM; Provincial Laboratory of Public Health for Southern Alberta,; Calgary, Canada.

Abstract: Two algorithms for screening sera for antibody to human immunodeficiency virus type 1 were compared for their efficiency in identifying a true-positive sample in a population with heterogeneous risk factors, using the criteria of specificity and positive predictive value (PPV). In the first algorithm, all sera were screened by using a single enzyme immunoassay (EIA) kit, and a specificity of 98.6% and a PPV of 69.3% was calculated for true-positive sera. The second algorithm employed two different EIA kits in parallel to screen each sample. In the first instance, a specificity and a PPV of 100% was calculated if a positive sample was defined as reactive by both EIA kits; in the second, a specificity of 99.97% and a PPV of 99.4% was obtained if this criterion was extended to include a combination of one reactive and one equivocal result obtained with the two EIA kits.
Keywords: Algorithms Comparative Study Diagnostic Errors Evaluation Studies Human HIV Antibodies/*BLOOD HIV Seropositivity/*DIAGNOSIS/IMMUNOLOGY HIV-1/*IMMUNOLOGY *Immunoenzyme Techniques/STATISTICS & NUMER DATA Risk Factors Sensitivity and Specificity JOURNAL ARTICLE

KWDalgorithmscomparativestudydiagnosticerrorsevaluationstudieshumanhivantibodies/KWDbloodhivseropositivity/KWDdiagnosis/immunologyhiv-1/KWDimmunologyKWDimmunoenzymetechniques/statistics&numerdatariskfactorssensitivityandspecificityjournalarticle
920530
M9250909

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .